By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Editas Medicine 

300 Third Street, First Floor

Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-401-9000 Fax: n/a


Editas Medicine is a transformative genome editing company founded by world leaders in the fields of genome editing, protein engineering, and molecular and structural biology, with specific expertise in CRISPR/Cas9 and TALENs technologies.

The company's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level. The company has generated substantial patent filings and has access to intellectual property covering foundational genome editing technologies, as well as essential advancements and enablements that will uniquely allow the company to translate early findings into viable human therapeutic products.

Editas was founded in 2013 with $43 million in Series A venture capital financing led by leading health care venture capital firms Flagship Ventures, Polaris Partners and Third Rock Ventures with participation from Partners Innovation Fund.

Key Statistics

Ownership: Private

Web Site: Editas Medicine
Employees: n/a


Start Up

Company News
Bill & Melinda Gates Foundation, Crossovers Dump $120 Million Into Editas Medicine to Advance Genome Editing 8/10/2015 6:04:42 AM
Editas Medicine Named A 2015 Technology Pioneer By World Economic Forum 8/5/2015 11:25:59 AM
Editas Medicine Appoints Andrew Hack, M.D., Ph.D., As Chief Financial Officer 7/1/2015 10:47:09 AM
Editas Medicine, Juno Therapeutics (JUNO) Hammer Out $727 Million CAR T R&D Deal 5/27/2015 5:39:20 AM
Editas Medicine Announces Six Scientific Presentations At The American Society Of Gene And Cell Therapy 18th Annual Meeting 5/6/2015 11:58:24 AM
Vic Myer, Ph.D. Joins Editas Medicine As Chief Technology Officer 4/27/2015 11:30:13 AM
Editas Medicine Reports New Data Demonstrating Potential Of CRISPR/Cas9 Construct As Novel Gene Repair Mechanism 3/2/2015 11:32:06 AM
Editas Medicine Reports New Data Characterizing Novel Properties Of Staphylococcus Aureus Cas9 As A Tool For CRISPR-Based Genome Engineering 1/12/2015 11:14:36 AM
Editas Medicine Licenses Genome Editing Technology From Broad Institute And Harvard University 12/1/2014 2:55:17 PM
Editas Medicine Licenses Genome Editing Technology From Massachusetts General Hospital 12/1/2014 12:14:33 PM